NMR diagnostics by means of a plastic sample container
Sample containers and methods for employing the same in in-vitro nuclear magnetic resonance measurements are provided. The sample containers are made of a material that comprises one or more polymeric materials.
1. A method for obtaining a T 2 time domain signal of a blood sample, the method comprising using a nuclear magnetic resonance device to perform the steps of:
(a) applying a radiofrequency CPMG pulse sequence in the presence of a magnetic field of from 0.2 to 2.0 Tesla to the blood sample having an estimated T 2 value and a sample container containing the blood sample, resulting in an NMR signal associated with the blood sample and an NMR signal associated with the sample container, wherein the sample container comprises a polymeric material, and wherein the contribution of the NMR signal associated with the sample container to the T 2 time domain signal of the blood sample is reduced by using a CPMG pulse sequence having acquisition time greater than five times the estimated T 2 value of the blood sample;
(b) acquiring the resulting NMR signals to obtain raw data; and
(c) processing the resulting NMR signals to obtain the T 2 time domain signal of the blood sample,
wherein the estimated T 2 value of the blood sample is determined, prior to step (a), by (i) using a nuclear magnetic resonance device to acquire NMR signals of the blood and a sample container containing the blood sample to produce whole raw data, (ii) using a processor to computationally discriminate a contribution from the sample container to the whole raw data to obtain sample data, partly or completely, free of the contribution from the sample container; and (iii) calculating from the sample data the estimated T 2 value of the blood sample.
2. The method of claim 1 , wherein the material of the sample container comprises more than 90% by weight of the sample container of the one or more polymeric materials.
3. The method of claim 1 , wherein the sample container further contains magnetic particles functionalized with binding moieties, the binding moieties being able to bind to analyte in the blood sample, the method further comprising the step of exposing the blood sample container to conditions suitable for the binding moieties and analyte in the blood sample to bind prior to acquisition of the NMR signals.
4. The method of claim 3 , wherein the analyte comprises at least one member selected from the group consisting of a protein, a peptide, a polypeptide, an amino acid, a nucleic acid, an oligonucleotide, a therapeutic agent, a metabolite of a therapeutic agent, RNA, DNA, an antibody, an organism, a virus, a bacteria, a carbohydrate, a polysaccharide, glucose, an ion or a small molecule.
5. The method of claim 3 , wherein the binding moieties are oligonucleotide binding moieties, polypeptide binding moieties, antibody binding moieties or polysaccharide binding moieties or synthetic small molecule binding moieties.